Story perspectives

Pancreatic Combo Shows 92% Response; Stocks Surge 43%

6/9/2026

Summary

Story summary

Data showed a 92% objective response rate, 90% six-month progression-free survival and 100% disease-control for the vopimetostat-daraxonrasib combo in 12 pancreatic cancer patients.
Tango’s shares and Revolution Medicines’ stock rose after the release, up 43% to $28.94 and just under 1% to $150.62 respectively.
The firms will advance the regimen to Phase 3 as a first-line treatment for MTAP-deleted pancreatic cancer, using a lower 100 mg daraxonrasib dose that may cut toxicity.

1 of 1

Story summary

Data showed a 92% objective response rate, 90% six-month progression-free survival and 100% disease-control for the vopimetostat-daraxonrasib combo in 12 pancreatic cancer patients.
Tango’s shares and Revolution Medicines’ stock rose after the release, up 43% to $28.94 and just under 1% to $150.62 respectively.
The firms will advance the regimen to Phase 3 as a first-line treatment for MTAP-deleted pancreatic cancer, using a lower 100 mg daraxonrasib dose that may cut toxicity.